-
1Academic Journal
Συγγραφείς: E. V. Belousova, T. V. Sokolovskaya, N. M. Kislitsyna, Е. В. Белоусова, Т. В. Соколовская, Н. М. Кислицына
Πηγή: National Journal glaucoma; Том 20, № 1 (2021); 55-64 ; Национальный журнал Глаукома; Том 20, № 1 (2021); 55-64 ; 2311-6862 ; 2078-4104
Θεματικοί όροι: афлиберцепт, filtration surgery, intraocular pressure, vascular endothelial growth factor, angiogenesis, bevacizumab, ranibizumab, aflibercept, фильтрационные хирургические вмешательства, внутриглазное давление, сосудистый фактор роста эндотелия сосудов, ангиогенез, бевацизумаб, ранибизумаб
Περιγραφή αρχείου: application/pdf
Relation: https://www.glaucomajournal.ru/jour/article/view/316/324; Рыков С.А., Новак Н.В. Эффективность комбинированного метода хирургического лечения вторичной неоваскулярной глаукомы. Офтальмология. Восточная Европа. 2018; 8(2):206-211.; Бабушкин А.Э. К вопросу о лечении неоваскулярной глаукомы. Точка зрения. Восток – Запад. 2019; 2:120-123. doi:10.25276/2410-1257-2019-2-120-123; Зотов А.С., Ефремова Т.Г., Нестерова Е.С., Солодкова Е.Г., Балалин С.В. Применение ингибиторов ангиогенеза в комплексном лечении неоваскулярной глаукомы. Современные технологии в офтальмологии. 2019; 4(29):108-111. doi:10.25276/2312-4911-2019-4-108-111; Карпилова М.А., Дуржинская М.Х. Анти-VEGF-препараты в лечении неоваскулярной глаукомы. Вестник офтальмологии. 2019; 135(5-2):299-304. doi:10.17116/oftalma2019135052299; Sun C., Zhang H., Jiang J., Li Y., Nie C., Gu J., Luo L., Wang Z. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2019 Dec 4. doi:10.1007/s10792-019-01207-4; Du J., Patrie J.T., Prum B.E., Netland P.A., Shildkrot Y.E. Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019; 28(12):1035-1040. doi:10.1097/IJG.0000000000001382; Chen H.J., Ma Z.Z., Li Y., Wang C.G. Change of Vascular Endothelial Growth Factor levels following vitrectomy in eyes with proliferative diabetic retinopathy. J Ophthalmol. 2019; Oct 23;2019:6764932. doi:10.1155/2019/6764932; Sun C., Zhang H.S., Yan Y.J., Zhao T., Li A.H., Tang Y., Wang Z.J. Early vitrectomy combined with pan retinal photocoagulation, antivascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma. Chin Med J (Engl). 2019; 132(20):2518-2520. doi:10.1097/CM9.0000000000000482; Rong A.J., Swaminathan S.S., Vanner E.A., Parrish R.K. 2nd. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol. 2019; 204:62-69. doi:10.1016/j.ajo.2019.02.038; Sakamoto M., Hashimoto R., Yoshida I., Ubuka M., Maeno T. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. Clin Ophthalmol. 2018; 12:2323-2329. doi:10.2147/OPTH.S184959.; Seibold L.K., Sherwood M.B., Kahook M.Y. Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530–550. doi:10.1016/j.survophthal.2012.01.008; Saeedi O.J., Jefferys J.L., Solus J.F., Jampel H.D., Quigley H.A. Risk factors for adverse consequences of low intraocular pressure after trabeculectomy. J Glaucoma. 2014; 23(1):e60–8. doi:10.1097/IJG.0000000000000008; Daneshvar R. Anti-VEGF agents and glaucoma filtering surgery. J Ophthalmic Vis Res. 2013; 8(2):182–186. PMID: 23943695; Park S.C., Su D., Tello C. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther. 2012; 12(12):1641–1647. doi:10.1517/14712598.2012.721772; SooHoo J.R., Seibold L.K., Kahook M.Y. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013; 28(3):165–172. doi:10.3109/08820538.2012.730103; Kim M., Lee C., Payne R., Yue B.Y., Chang J.H., Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol. 2015; 60(6):524–535. doi:10.1016/j.survophthal.2015.04.003; Kitnarong N., Sriyakul C., Chinwattanakul S. A prospective study to evaluate intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma. Ophthalmol Ther. 2015; 4(1):33–41. doi:10.1007/s40123-015-0033-3; SooHoo J.R., Seibold L.K., Pantcheva M.B., Kahook M.Y. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015; 43(9):803–807. doi:10.1111/ceo.12559; Magdelaine-Beuzelin C., Pinault C., Paintaud G., Watier H. Therapeutic antibodies in ophthalmology: old is new again. MAbs. 2010; 2(2):176–180. doi:10.4161/mabs.2.2.11205; Simha A., Braganza A., Abraham L., Samuel P., Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013; 10:CD007920. doi:10.1002/14651858; Waisbourd M., Shemesh G., Kurtz S., Rachmiel R., Moisseiev E., ZayitSoudri S., Loewenstein A., Barequet I. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014; 93(3-4): 108–112. doi:10.1159/000358600; Duch S., Buchacra O., Milla E., Andreu D., Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009; 18(2):140–143. doi:10.1097/IJG.0b013e318170a747; Luke J., Nassar K., Luke M., Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10):2403–2413. doi:10.1007/s00417-013-2428-y; Grover S., Gupta S., Sharma R., Brar V.S., Chalam K.V. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009; 93(2):273–274. doi:10.1136/bjo.2008.145714; Sugimoto Y., Mochizuki H., Okumichi H., Takumida M., Takamatsu M., Kawamata S., Kiuchi Y. et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1601–1609. doi:10.1007/s00417-010-1406-x; Muhsen S., Compan J., Lai T., Kranemann C., Birt C. Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma. Int J Ophthalmol. 2019; 12(10):1567-1574. doi:10.18240/ijo.2019.10.08; Elwehidy A.S., Bayoumi N.H., Badawi A.E., Hagras S.M., Abdelkader A. Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma. Asia Pac J Ophthalmol (Phila). 2019; 8(4):308-313. doi:10.1097/APO.0000000000000248; Li Z., Van Bergen T., Van de Veire S., Van de Vel I., Moreau H., Dewerchin M., Maudgal P.C., Zeyen T., Spileers W., Moons L., Stalmans I. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009; 50(11):5217–5225. doi:10.1167/iovs.08-2662; Memarzadeh F., Varma R., Lin L.T., Parikh J.G., Dustin L., Alcaraz A., Eliott D. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009; 50(7):3233–3237. doi:10.1167/iovs.08-2441; Ozgonul C., Mumcuoglu T., Gunal A. The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res. 2014; 39(5):451–459. doi:10.3109/02713683.2013.851704; Sengupta S., Venkatesh R., Ravindran R.D. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma. 2012; 21(7):450–459. doi:10.1097/IJG.0b013e31821826b2; Tai T.Y., Moster M.R., Pro M.J., Myers J.S., Katz L.J. Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma. 2015; 24(4):311–315. doi:10.1097/IJG.0b013e31829f9bd3; Pro M.J., Freidl K.B., Neylan C.J., Sawchyn A.K., Wizov S.S., Moster M.R. Ranibizumab versus mitomycin C in primary trabeculectomy — a pilot study. Curr Eye Res. 2015; 40(5):510–515. doi:10.3109/02713683.2014.935441; Nilforushan N., Yadgari M., Kish S.K., Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012; 153(2):352–7.e1. doi:10.1016/j.ajo.2011.08.005; Akkan J.U., Cilsim S. Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study. J Glaucoma. 2015; 24(1):1–8. doi:10.1097/IJG.0b013e318287abf3; Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., Nugent A.K., Hirooka K., Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50(10):4807–13. doi:10.1167/iovs.08-3148; Jurkowska-Dudzinґska J., Kosior-Jarecka E., Zarnowski T. Comparison of the use of 5-flfluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Exp Ophthalmol. 2012; 40(4):e135– 42. doi:10.1111/j.1442-9071.2011.02608.x; Vandewalle E., Abegão Pinto L., Van Bergen T., Spielberg L., Fieuws S., Moons L., Spileers W., Zeyen T., Stalmans I. et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014; 98(1):73–78. doi:10.1136/bjophthalmol-2013-303966; Hau S., Barton K. Corneal complications of glaucoma surgery. Curr Opin Ophthalmol. 2009; 20(2):131–136. doi:10.1097/ICU.0b013e328325a54b; Yoeruek E., Spitzer M.S., Tatar O., Aisenbrey S., Bartz-Schmidt K.U., Szurman P. Safety profifile of bevacizumab on cultured human corneal cells. Cornea. 2007; 26(8):977–982. doi:10.1097/ICO.0b013e3180de1d0a; Bochmann F., Kaufmann C., Becht C.N., Guber I., Kaiser M., Bachmann L.M., Thiel M.A. et al. ISRCTN12125882-inflfluence of topical anti-VEGF Ranibizumab) on the outcome of filtration surgery for glaucoma-study protocol. BMC Ophthalmol. 2011; 11:1. doi:10.1186/1471-2415-11-1; Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., Miyazono K., Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005; 118(Pt 16):3759–68. doi:10.1242/jcs.02483; Liu X., Du L., Li N. The effects of bevacizumab in augmenting trabeculectomy for glaucoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(15):e3223. doi:10.1097/MD.0000000000003223; https://www.glaucomajournal.ru/jour/article/view/316